Last reviewed · How we verify
Inhaled LABA use
Long-acting beta2-adrenergic receptor agonist
Long-acting beta2-adrenergic receptor agonist Used for Chronic obstructive pulmonary disease, Asthma.
At a glance
| Generic name | Inhaled LABA use |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta2-adrenergic receptor agonist |
| Target | beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Inhaled LABAs work by stimulating the beta2-adrenergic receptors in the lungs, causing bronchodilation and improved airflow.
Approved indications
- Chronic obstructive pulmonary disease
- Asthma
Common side effects
- Cough
- Headache
- Oral candidiasis
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Improving the Quality of Care for Asthma Patients at Risk of Exacerbations (NA)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- Immuno-inflammatory Response of Erdosteine in COPD (NA)
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
- Efficacy of a Smart add-on Device in Combination With a Triple Treatment in Asthma Patients on Inhaler Technique and Adherence
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled LABA use CI brief — competitive landscape report
- Inhaled LABA use updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI